减低强度异基因干细胞移植作为惰性淋巴瘤或慢性淋巴细胞白血病患者自体干细胞移植失败后的挽救治疗。 - Suppr | 超能文献

Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.

作者信息

Dreger P, Glass B, Seyfarth B, Humpe A, Claviez A, von Neuhoff N, Suttorp M, Schoch R, Schmitz N

出版信息

Bone Marrow Transplant. 2000 Dec;26(12):1361-2. doi: 10.1038/sj.bmt.1702722.

DOI:10.1038/sj.bmt.1702722

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.减低强度异基因干细胞移植作为惰性淋巴瘤或慢性淋巴细胞白血病患者自体干细胞移植失败后的挽救治疗。

Bone Marrow Transplant. 2000 Dec;26(12):1361-2. doi: 10.1038/sj.bmt.1702722.

2

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.异基因干细胞移植后复发的惰性淋巴瘤中供体淋巴细胞输注的移植物抗淋巴瘤效应

Bone Marrow Transplant. 2003 Dec;32(12):1159-63. doi: 10.1038/sj.bmt.1704290.

3

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.减低强度预处理和异基因干细胞移植后慢性淋巴细胞白血病移植物抗白血病效应的证据：德国移植协作研究组

J Clin Oncol. 2003 Jul 15;21(14):2747-53. doi: 10.1200/JCO.2003.12.011.

4

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.基于抗胸腺细胞球蛋白的减低剂量预处理异基因干细胞移植后的移植物抗骨髓瘤效应

Bone Marrow Transplant. 2004 Jul;34(1):77-84. doi: 10.1038/sj.bmt.1704531.

5

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.氟达拉滨、环磷酰胺和利妥昔单抗用于治疗慢性淋巴细胞白血病或惰性非霍奇金淋巴瘤患者。

Cancer. 2006 Jun 1;106(11):2412-20. doi: 10.1002/cncr.21882.

6

High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.惰性非霍奇金淋巴瘤异基因干细胞移植后对供体淋巴细胞输注的高反应率。

Biol Blood Marrow Transplant. 2008 Jan;14(1):50-8. doi: 10.1016/j.bbmt.2007.04.013.

7

Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.减低强度异基因造血干细胞移植后早期供体植入的建立，以增强移植物抗淋巴瘤效应治疗难治性淋巴瘤。

Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9. doi: 10.1053/bbmt.2003.50008.

8

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.大剂量卡莫司汀、依托泊苷和环磷酰胺序贯异基因造血细胞移植治疗非霍奇金淋巴瘤

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11. doi: 10.1016/j.bbmt.2006.02.009.

9

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.复发至先前自体移植状态和慢性移植物抗宿主病是多发性骨髓瘤患者接受基于美法仑/氟达拉滨的减低剂量异基因干细胞移植结局的最强预后因素。

Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002.

10

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.非霍奇金淋巴瘤异基因移植中减低强度与传统清髓方案的比较。

Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34. doi: 10.1016/j.bbmt.2006.08.035.

引用本文的文献

1

Hematopoietic Stem Cells and Regeneration.造血干细胞与再生

Cold Spring Harb Perspect Biol. 2022 Aug 1;14(8):a040774. doi: 10.1101/cshperspect.a040774.

2

Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.造血干细胞移植——50年的发展历程与未来展望

Rambam Maimonides Med J. 2014 Oct 29;5(4):e0028. doi: 10.5041/RMMJ.10162. eCollection 2014 Oct.